<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04794738</url>
  </required_header>
  <id_info>
    <org_study_id>SHR8554-202</org_study_id>
    <nct_id>NCT04794738</nct_id>
  </id_info>
  <brief_title>A Clinical Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery</brief_title>
  <official_title>A Phase II/III, Randomized, Double-Blind, Placebo- and Active-controlled Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the analgesic efficacy of IV SHR8554 compared with&#xD;
      placebo and morphine in patients with acute postoperative pain following orthopedic surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Sum of Pain Intensity Differences in Pain Score Over 48 Hours in the rest state</measure>
    <time_frame>48-hours</time_frame>
    <description>Pain intensity will be evaluated using an 11-point (0-10) Numeric Pain Rating Scale (NPRS), with higher numbers indicating a higher pain intensity, administered over 48 hours. Time weighted average change from baseline is calculated using the following: time weighted sum of pain intensity differences (SPID) divided by a constant (48 hours) to yield values on the 0-10 NPRS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Sum of Pain Intensity Differences in Pain Score Over 6、12、48 、12-24、24-48 Hours under static condition</measure>
    <time_frame>48-hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Sum of Pain Intensity Differences in Pain Score Over 6、12、24、48 、12-24、24-48 Hours under moving condition</measure>
    <time_frame>48-hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of first use of remedial analgesic medication</measure>
    <time_frame>48-hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative use of remedial analgesics from 0h to 48h</measure>
    <time_frame>48-hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant ' satisfaction score for analgesia treatment</measure>
    <time_frame>48-hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator satisfaction score for analgesia treatment</measure>
    <time_frame>48-hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR8554</intervention_name>
    <description>SHR8554 Injection; high dose</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR8554</intervention_name>
    <description>SHR8554 Injection; low dose</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <description>Saline Solution</description>
    <arm_group_label>Treatment group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Morphine</description>
    <arm_group_label>Treatment group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to provide a written informed consent&#xD;
&#xD;
          2. Subjects requiring elective general anesthesia orthopedic surgery&#xD;
&#xD;
          3. Conform to the ASA Physical Status Classification&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a history of difficult airway&#xD;
&#xD;
          2. Subjects with a history of reflux esophagitis&#xD;
&#xD;
          3. Subjects with a history of mental illness&#xD;
&#xD;
          4. Subjects with poor blood pressure control&#xD;
&#xD;
          5. Transcutaneous oxygen saturation (SpO2) &lt;90%&#xD;
&#xD;
          6. Random blood glucose ≥11.1mmol/L&#xD;
&#xD;
          7. Subjects with abnormal liver function&#xD;
&#xD;
          8. allergies to opioids and other medications that may be used during the trial&#xD;
&#xD;
          9. Pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yong Cao, M.M</last_name>
    <phone>+0518-81220121</phone>
    <email>caoyong@hrs.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Jiaotong University School of Medicine,Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weifeng Yu, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

